Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 25 2025
0mins
Should l Buy ?
Source: Reuters
Merck KGaA Acquisition Talks: Merck KGaA is in late-stage negotiations to acquire U.S.-based SpringWorks Therapeutics for approximately $3.5 billion, which would enhance its cancer treatment portfolio and provide access to a recently approved rare disease drug.
Market Impact and Challenges: The potential acquisition comes as Merck faces slowing sales from its cancer drug Bavencio and challenges with its multiple sclerosis treatment Mavenclad, while SpringWorks has seen a decline in share value since February.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
